Glidib, tablets 80 mg 60 pcs

Glediab is hypoglycemic.

Stimulates muscle glycogen synthetase activity, insulin secretion, potentiates insulin-secretory action of glucose, increases peripheral tissue sensitivity to insulin.

Pharmacodynamics

Shortens the time from the time of eating to the beginning of insulin secretion. Restores the early peak of insulin secretion, lowers the peak of hyperglycemia. In addition to action on carbohydrate metabolism, it affects the microcirculation. It reduces platelet adhesion and aggregation, normalizes vascular permeability and prevents the development of microthrombosis and atherosclerosis, restores the process of physiological parietal fibrinolysis; prevents an increased vascular response to adrenaline in microangiopathies. Slows down the development of diabetic retinopathy at the nonproliferative stage; with long-term use, reduces proteinuria in diabetic nephropathy; promotes weight loss in obese patients with an appropriate diet.

Pharmacokinetics

It is well absorbed from gastrointestinal tract, Cmax after oral dosage of 80 mg is reached in 4 hours. Binding to plasma proteins is 94%. T1/2 is about 12 hours. Metabolized in the liver to form several metabolites. Less than 1% is excreted unchanged in the urine, 12% in the feces as metabolites.

Indications

Type II diabetes mellitus in adults.

Active ingredient

Composition

Active substance:

gliclazide 80 mg

How to take, the dosage

The dose is set individually, depending on the patient’s age, clinical manifestations of the disease and the level of glycemia on an empty stomach and 2 hours after meals. The initial dose is 80 mg/day, the average dose is 160 mg/day, and the maximum dose is 320 mg/day.

Glidib® is taken orally 2 times daily (morning and evening) 30-60 min before a meal.

Interaction

Strengthening of hypoglycemic action of Glidiab® preparation is observed during concomitant use with ACE inhibitors (captopril, enalapril), histamine H2-receptor blockers (cimetidine), antifungal drugs (miconazole, fluconazole), NSAIDs (phenylbutazone, indomethacin, diclofenac), fibrates (clofibrate, besafibrate), anti-tuberculosis drugs (etionamide), salicylates, indirect coumarin-type anticoagulants, anabolic steroids, Beta-adrenoblockers, cyclophosphamide, chloramphenicol, MAO inhibitors, prolonged sulfonamides, phenfluramine, fluoxetine, pentoxifylline, guanethidine, theophylline, drugs Inhibitors of tubulin secretion, reserpine, bromocriptine, disopyramide, pyridoxine, allopurinol, ethanol and ethanol-containing drugs, and other hypoglycemic drugs (acarbose, biguanides, insulin).

. The hypoglycemic action of Glidiab® preparation is decreased when concomitant use with barbiturates, GCS, sympathomimetics (epinephrine, clonidine, ritodrine, salbutamol, terbutaline), phenytoin, slow calcium channel blockers, carboanhydrase inhibitors (acetazolamide), thiazide diuretics, chlorothalidone, furosemide, triamterene, with asparaginase, baclofen, danazol, diazoxide, isoniazid, morphine, glucagon, rifampicin, with thyroid hormones, lithium salts, in high doses – with nicotinic acid, chlorpromazine, estrogens and oral contraceptives containing them.

In interaction with ethanol a disulfiram-like reaction may occur. Glidyab® increases the risk of ventricular extrasystole while taking cardiac glycosides. Beta-adrenoblockers, clonidine, reserpine, guanethidine may mask clinical manifestations of hypoglycemia.

Special Instructions

Treatment is carried out in combination with a low-calorie, low-carbohydrate diet. During treatment, glycemia levels should be monitored regularly on an empty stomach and after meals.

In case of surgical interventions or in decompensation of diabetes it is necessary to consider the possibility of using insulin drugs. Patients should be warned about the increased risk of hypoglycemia if they are taking ethanol, NSAIDs, and fasting.

In case of ethanol administration, disulfiram-like syndrome (abdominal pain, nausea, vomiting, headache) may also develop. It is necessary to correct the dose of the drug in case of physical or emotional overexertion, changes in diet. Particularly sensitive to the action of hypoglycemic drugs are elderly people; patients who do not receive a balanced diet; weakened patients; patients suffering from pituitary-adrenal insufficiency.

Impact on driving and operating machinery

At the beginning of treatment, during dose adjustment, patients who are prone to developing hypoglycemia are not recommended to engage in activities that require increased attention and rapid psychomotor reactions.

Contraindications

Side effects

Endocrine system disorders: hypoglycemia (in case of violation of the dosing regimen and inadequate diet) – headache, fatigue, feeling of hunger, sweating, sudden weakness, aggressiveness, anxiety, irritability, inattention, inability to concentrate and slow reaction, depression, visual disturbance, aphasia, tremor, feeling helpless, sensory disturbances, dizziness, loss of self-control, delirium, seizures, hypersomnia, loss of consciousness, shallow breathing, bradycardia.

Digestive system disorders: dyspepsia (nausea, diarrhea, feeling of heaviness in epigastrium), anorexia (severity decreases when taking the drug with meals), liver function disorders (cholestatic jaundice, increased liver transaminase activity).

Hematopoietic system disorders: anemia, thrombocytopenia, leukopenia. Allergic reactions: itching, urticaria, maculopapular rash.

Overdose

Symptoms: development of hypoglycemia up to hypoglycemic coma is possible.

Treatment: if the patient is conscious, dextrose (glucose) or sugar solution is administered orally. In case of loss of consciousness, IV 40% dextrose solution is administered, IV 1-2 mg of glucagon. After recovery of consciousness, the patient should be given food rich in easily digestible carbohydrates, in order to avoid a recurrence of hypoglycemia.

Pregnancy use

The drug is contraindicated in pregnancy.

Breastfeeding should be stopped if it is necessary to use during lactation.

Similarities